Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.4% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) fell 3.4% during trading on Wednesday . The company traded as low as $6.81 and last traded at $6.88. 4,370,890 shares changed hands during trading, a decline of 33% from the average session volume of 6,568,276 shares. The stock had previously closed at $7.12.

Analyst Ratings Changes

Several research firms have recently weighed in on RXRX. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Jefferies Financial Group dropped their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Finally, Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Stock Down 5.6 %

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The business has a 50-day simple moving average of $6.77 and a two-hundred day simple moving average of $7.23. The stock has a market capitalization of $1.93 billion, a P/E ratio of -4.39 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the firm earned ($0.43) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% on a year-over-year basis. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the transaction, the chief operating officer now directly owns 521,138 shares in the company, valued at $3,647,966. This trade represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 107,788 shares of company stock worth $724,691 over the last three months. 15.75% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Franklin Resources Inc. grew its holdings in shares of Recursion Pharmaceuticals by 58.9% during the 3rd quarter. Franklin Resources Inc. now owns 18,963 shares of the company’s stock worth $127,000 after purchasing an additional 7,027 shares in the last quarter. Sanctuary Advisors LLC bought a new position in Recursion Pharmaceuticals in the third quarter worth approximately $89,000. Geode Capital Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after purchasing an additional 656,003 shares in the last quarter. Barclays PLC increased its position in shares of Recursion Pharmaceuticals by 53.9% during the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock worth $4,596,000 after acquiring an additional 244,278 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in Recursion Pharmaceuticals during the 3rd quarter valued at about $692,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.